| Pharmaceutical Information |
| Drug Name |
Efinaconazole |
| Drug ID |
BADD_D00750 |
| Description |
Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia. |
| Indications and Usage |
Indicated in the treatment of fungal infection of the nail, known as onychomycosis. |
| Marketing Status |
Prescription |
| ATC Code |
D01AC19 |
| DrugBank ID |
DB09040
|
| KEGG ID |
D10021
|
| MeSH ID |
C431707
|
| PubChem ID |
489181
|
| TTD Drug ID |
D0G4BI
|
| NDC Product Code |
66064-1024; 46438-0644; 51265-541; 0187-5400; 76397-017; 70600-001; 58175-0606; 51686-0012; 76397-018; 51557-001; 76397-006; 65015-896; 46016-1642; 68259-1314; 66039-930 |
| Synonyms |
efinaconazole | KP 103 | KP103 | KP-103 | Jublia |
|
| Chemical Information |
| Molecular Formula |
C18H22F2N4O |
| CAS Registry Number |
164650-44-6 |
| SMILES |
CC(C(CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3 |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
